$BFRI
Biofrontera Inc. Stock $bfri

$bfri Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000149315223027701 Filed on August 11, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2022 Q2
Revenue	$8.896M	$5.848M	$4.457M
YoY Change	105.83%	31.21%	-23.88%
Cost Of Revenue	$4.590M	$2.888M	$2.554M
YoY Change	106.29%	13.08%	-17.82%
Gross Profit	$4.310M	$2.960M	$1.903M
YoY Change	105.53%	55.54%	-30.72%
Gross Profit Margin	48.45%	50.62%	42.7%
Selling, General & Admin	$8.619M	$11.46M	$9.669M
YoY Change	11.0%	18.48%	74.15%
% of Gross Profit	199.98%	387.03%	508.09%
Research & Development	$33.00K	$11.00K
YoY Change
% of Gross Profit	0.77%	0.37%
Depreciation & Amortization	$130.0K	$126.0K	$26.00K
YoY Change	-0.76%	384.62%	-21.21%
% of Gross Profit	3.02%	4.26%	1.37%
Operating Expenses	$13.52M	$14.55M	$10.67M
YoY Change	69.78%	36.35%	11.81%
Operating Profit	-$4.620M	-$8.699M	-$6.212M
YoY Change	26.96%	40.04%	68.48%
Interest Expense	$142.0K	$79.00K	$38.00K
YoY Change	59.55%	107.89%	-55.29%
% of Operating Profit
Other Income/Expense, Net	-$1.721M	-$1.124M	$5.362M
YoY Change	-260.24%	-120.96%	7560.0%
Pretax Income	-$6.341M	-$9.823M	-$850.0K
YoY Change	147.21%	1055.65%	-76.5%
Income Tax	$1.000K	$14.00K
% Of Pretax Income
Net Earnings	-$6.342M	-$9.837M	-$850.0K
YoY Change	147.16%	1057.29%	-76.78%
Net Earnings / Revenue	-71.29%	-168.21%	-19.07%
Basic Earnings Per Share	-$4.64	-$7.23	-$0.05
Diluted Earnings Per Share	-$4.64	-$7.23	-$0.05
COMMON SHARES
Basic Shares Outstanding	1.368M shares	26.70M shares	18.82M shares
Diluted Shares Outstanding	1.367M shares	1.361M shares	18.82M shares

Balance Sheet

Concept	2023 Q3	2023 Q2	2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$6.760M	$10.39M	$32.04M
YoY Change	-75.51%	-67.58%	909.8%
Cash & Equivalents	$3.422M	$4.453M	$31.91M
Short-Term Investments	$3.340M	$5.935M	$128.0K
Other Short-Term Assets	$270.0K	$929.0K	$1.086M
YoY Change	-62.55%	-14.46%	2.94%
Inventory	$16.07M	$14.79M	$8.808M
Prepaid Expenses			$599.0K
Receivables	$6.510M	$6.194M	$5.046M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$29.61M	$32.30M	$46.98M
YoY Change	-38.94%	-31.26%	269.06%
LONG-TERM ASSETS
Property, Plant & Equipment	$154.0K	$175.0K	$248.0K
YoY Change	-31.25%	-29.44%	-21.02%
Goodwill
YoY Change
Intangibles	$2.718M	$2.823M	$3.241M
YoY Change	-13.33%	-12.9%
Long-Term Investments
YoY Change
Other Assets	$490.0K	$504.0K	$343.0K
YoY Change	24.68%	46.94%	-65.42%
Total Long-Term Assets	$4.493M	$4.609M	$6.645M
YoY Change	-31.57%	-30.64%	33.84%
TOTAL ASSETS
Total Short-Term Assets	$29.61M	$32.30M	$46.98M
Total Long-Term Assets	$4.493M	$4.609M	$6.645M
Total Assets	$34.10M	$36.91M	$53.63M
YoY Change	-38.06%	-31.18%	203.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.620M	$1.243M	$931.0K
YoY Change	3307.11%	33.51%	-0.11%
Accrued Expenses	$11.04M	$10.74M	$9.413M
YoY Change	16.91%	14.06%	304.86%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$29.12M	$25.35M	$14.88M
YoY Change	69.89%	70.42%	269.04%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$38.00K	$40.00K	$5.650M
YoY Change	-99.33%	-99.29%	-62.41%
Total Long-Term Liabilities	$38.00K	$40.00K	$5.650M
YoY Change	-99.33%	-99.29%	-62.41%
TOTAL LIABILITIES
Total Short-Term Liabilities	$29.12M	$25.35M	$14.88M
Total Long-Term Liabilities	$38.00K	$40.00K	$5.650M
Total Liabilities	$33.07M	$29.73M	$36.39M
YoY Change	1.85%	-18.3%	90.92%
SHAREHOLDERS EQUITY
Retained Earnings	-$103.2M	-$96.80M	-$74.20M
YoY Change	34.55%	30.46%
Common Stock	$1.000K	$27.00K	$19.00K
YoY Change	-95.65%	42.11%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.038M	$7.173M	$17.23M
YoY Change
Total Liabilities & Shareholders Equity	$34.10M	$36.91M	$53.63M
YoY Change	-38.06%	-31.18%	203.06%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2022 Q2
OPERATING ACTIVITIES
Net Income	-$6.342M	-$9.837M	-$850.0K
YoY Change	147.16%	1057.29%	-76.78%
Depreciation, Depletion And Amortization	$130.0K	$126.0K	$26.00K
YoY Change	-0.76%	384.62%	-21.21%
Cash From Operating Activities	-$2.000M	-$10.34M	$125.0K
YoY Change	-66.34%	-8368.8%	-111.74%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	-$31.00K
YoY Change	-100.0%	-100.0%	933.33%
Acquisitions
YoY Change
Other Investing Activities	$380.0K	$178.0K
YoY Change	-112.53%
Cash From Investing Activities	$390.0K	$178.0K	-$31.00K
YoY Change	-112.85%	-674.19%	933.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	590.0K	1.106M	9.391M
YoY Change	-87.26%	-88.22%	-1916.44%
NET CHANGE
Cash From Operating Activities	-2.000M	-10.34M	125.0K
Cash From Investing Activities	390.0K	178.0K	-31.00K
Cash From Financing Activities	590.0K	1.106M	9.391M
Net Change In Cash	-1.020M	-9.052M	9.485M
YoY Change	-76.52%	-195.43%	-698.42%
FREE CASH FLOW
Cash From Operating Activities	-$2.000M	-$10.34M	$125.0K
Capital Expenditures	$0.00	$0.00	-$31.00K
Free Cash Flow	-$2.000M	-$10.34M	$156.0K
YoY Change	-66.33%	-6725.64%	-114.69%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	BFRI	Stock Options And Restricted Stock Units StockOptionsAndRestrictedStockUnits		shares
CY2023Q2	us-gaap	Preferred Stock Value PreferredStockValue		usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001858685
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2022Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent		usd
CY2023Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense		usd
CY2022Q2	us-gaap	Gain Loss On Investments GainLossOnInvestments		usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments		usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2022Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense		usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments		usd
	us-gaap	Inventory Write Down InventoryWriteDown		usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability		usd
	us-gaap	Proceeds From Sale Of Equity Securities Fv Ni ProceedsFromSaleOfEquitySecuritiesFvNi		usd
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit		usd
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity		usd
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	BFRI	Fair Value Warrant Issuance Of New Derivative Liabilities FairValueWarrantIssuanceOfNewDerivativeLiabilities		usd
CY2022Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments		usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments		usd
CY2022Q2	BFRI	Net Losses Recognized During Period On Equity Securities Sold NetLossesRecognizedDuringPeriodOnEquitySecuritiesSold		usd
	BFRI	Net Losses Recognized During Period On Equity Securities Sold NetLossesRecognizedDuringPeriodOnEquitySecuritiesSold		usd
CY2022Q2	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss		usd
	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss		usd
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2023Q2	BFRI	Stock Options And Restricted Stock Units StockOptionsAndRestrictedStockUnits		shares
CY2022Q2	BFRI	Stock Options And Restricted Stock Units StockOptionsAndRestrictedStockUnits		shares
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-40943
	dei	Entity Registrant Name EntityRegistrantName	Biofrontera Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-3765675
	dei	Entity Address Address Line1 EntityAddressAddressLine1	120 Presidential Way
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 330
	dei	Entity Address City Or Town EntityAddressCityOrTown	Woburn
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	01801
	dei	City Area Code CityAreaCode	(781)
	dei	Local Phone Number LocalPhoneNumber	245-1325
	dei	Entity Information Former Legal Or Registered Name EntityInformationFormerLegalOrRegisteredName	Not Applicable
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1367628	shares
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4453000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17208000	usd
CY2023Q2	us-gaap	Accounts Receivable Net AccountsReceivableNet	2193000	usd
CY2022Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	3748000	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	14785000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	7168000	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	929000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	810000	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	32296000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	43140000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	175000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	204000	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1107000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1375000	usd
CY2023Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2823000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3032000	usd
CY2023Q2	us-gaap	Other Assets OtherAssets	504000	usd
CY2022Q4	us-gaap	Other Assets OtherAssets	320000	usd
CY2023Q2	us-gaap	Assets Assets	36905000	usd
CY2022Q4	us-gaap	Assets Assets	50884000	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1243000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1278000	usd
CY2023Q2	BFRI	Accounts Payable Related Parties AccountsPayableRelatedParties	4657000	usd
CY2022Q4	BFRI	Accounts Payable Related Parties AccountsPayableRelatedParties	1312000	usd
CY2023Q2	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	7121000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	6942000	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	489000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	498000	usd
CY2023Q2	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	10736000	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	10864000	usd
CY2023Q2	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	1106000	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	25352000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	20894000	usd
CY2023Q2	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	2300000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	2400000	usd
CY2023Q2	BFRI	Warrant Liabilities Non Current WarrantLiabilitiesNonCurrent	1440000	usd
CY2022Q4	BFRI	Warrant Liabilities Non Current WarrantLiabilitiesNonCurrent	2843000	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	600000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	848000	usd
CY2023Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	40000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	21000	usd
CY2023Q2	us-gaap	Liabilities Liabilities	29732000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	27006000	usd
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2023Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	15000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	15000000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1367628	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1367628	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1359040	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1359040	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	27000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	27000	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	103980000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	103370000	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-96834000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-79519000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	7173000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	23878000	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	36905000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	50884000	usd
CY2023Q2	BFRI	Products Revenues Net ProductsRevenuesNet	5830000	usd
CY2022Q2	BFRI	Products Revenues Net ProductsRevenuesNet	4441000	usd
	BFRI	Products Revenues Net ProductsRevenuesNet	14544000	usd
	BFRI	Products Revenues Net ProductsRevenuesNet	14177000	usd
CY2023Q2	BFRI	Revenues Related Party RevenuesRelatedParty	18000	usd
CY2022Q2	BFRI	Revenues Related Party RevenuesRelatedParty	16000	usd
	BFRI	Revenues Related Party RevenuesRelatedParty	36000	usd
	BFRI	Revenues Related Party RevenuesRelatedParty	31000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5848000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4457000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	14580000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	14208000	usd
CY2023Q2	us-gaap	Related Parties Amount In Cost Of Sales RelatedPartiesAmountInCostOfSales	2772000	usd
CY2022Q2	us-gaap	Related Parties Amount In Cost Of Sales RelatedPartiesAmountInCostOfSales	2402000	usd
	us-gaap	Related Parties Amount In Cost Of Sales RelatedPartiesAmountInCostOfSales	7319000	usd
	us-gaap	Related Parties Amount In Cost Of Sales RelatedPartiesAmountInCostOfSales	7377000	usd
CY2023Q2	BFRI	Cost Of Revenues CostOfRevenues	116000	usd
CY2022Q2	BFRI	Cost Of Revenues CostOfRevenues	152000	usd
	BFRI	Cost Of Revenues CostOfRevenues	167000	usd
	BFRI	Cost Of Revenues CostOfRevenues	327000	usd
CY2023Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	11456000	usd
CY2022Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	9669000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	21254000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	17285000	usd
CY2023Q2	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	92000	usd
CY2022Q2	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	346000	usd
	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	119000	usd
	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	441000	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11000	usd
CY2023Q2	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	100000	usd
CY2022Q2	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-1900000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-100000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-1900000	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	14547000	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	10669000	usd
	us-gaap	Operating Expenses OperatingExpenses	28770000	usd
	us-gaap	Operating Expenses OperatingExpenses	23530000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-8699000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-6212000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-14190000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9322000	usd
CY2023Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-375000	usd
CY2022Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-5371000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1403000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-14082000	usd
CY2023Q2	us-gaap	Gain Loss On Investments GainLossOnInvestments	-1482000	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	-4424000	usd
CY2023Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-79000	usd
CY2022Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-38000	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-114000	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-71000	usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	62000	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	29000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	30000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	52000	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1124000	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	5362000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3105000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	14063000	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9823000	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-850000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-17295000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	4741000	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	14000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	20000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	30000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-9837000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-850000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-17315000	usd
	us-gaap	Net Income Loss NetIncomeLoss	4711000	usd
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-7.23
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.90
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-12.73
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	5.24
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-7.23
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.90
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-12.73
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	5.22
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1360739	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	941175	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1359894	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	898444	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1360739	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	941175	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1359894	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	902209	shares
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	16751000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	259000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-9837000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	7173000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	23878000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	610000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-17315000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-17315000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	7173000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	17416000	usd
CY2022Q2	BFRI	Stock Issued During Period Value Private Placement Issuance Costs StockIssuedDuringPeriodValuePrivatePlacementIssuanceCosts	116000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	551000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-850000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	17233000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	11338000	usd
	BFRI	Stock Issued During Period Value Private Placement Issuance Costs StockIssuedDuringPeriodValuePrivatePlacementIssuanceCosts	116000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1068000	usd
	us-gaap	Net Income Loss NetIncomeLoss	4711000	usd
	us-gaap	Net Income Loss NetIncomeLoss	4711000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	17233000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-17315000	usd
	us-gaap	Net Income Loss NetIncomeLoss	4711000	usd
	us-gaap	Depreciation Depreciation	44000	usd
	us-gaap	Depreciation Depreciation	54000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	265000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	209000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	209000	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-4424000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-100000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-1900000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1403000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-14082000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	610000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1068000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	100000	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	64000	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	133000	usd
	BFRI	Noncash Interest Expense NoncashInterestExpense	190000	usd
	BFRI	Noncash Interest Expense NoncashInterestExpense	179000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1491000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1650000	usd
	us-gaap	Increase Decrease In Due From Other Related Parties Current IncreaseDecreaseInDueFromOtherRelatedPartiesCurrent	-2397000	usd
	us-gaap	Increase Decrease In Due From Other Related Parties Current IncreaseDecreaseInDueFromOtherRelatedPartiesCurrent	-5602000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	302000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-3698000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	7617000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4449000	usd
	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	3380000	usd
	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	1280000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-255000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-107000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-240000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14025000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1987000	usd
	us-gaap	Proceeds From Sale Of Equity Securities Fv Ni ProceedsFromSaleOfEquitySecuritiesFvNi	178000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	14000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	36000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	164000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-36000	usd
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	5700000	usd
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	9391000	usd
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	4594000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1106000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9391000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-12755000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	7368000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	17408000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	24742000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4653000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	32110000	usd
	us-gaap	Interest Paid Net InterestPaidNet	4000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	30000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4500000	usd
CY2023Q2	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	5900000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17200000	usd
CY2022Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	10500000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-14200000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9300000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14000000.0	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2000000.0	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-96800000	usd
CY2023Q2	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	2400000	usd
CY2023Q3	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-20
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_846_eus-gaap--UseOfEstimates_zRulWTEKbB49" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zLzmNAwnJGpd">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the financial statements in accordance with U.S. GAAP requires the use of estimates and assumptions by management that affect the reported amounts of assets and liabilities, as well as disclosure of contingent assets and liabilities, as reported on the balance sheet date, and the reported amounts of revenues and expenses arising during the reporting period. The main areas in which assumptions, estimates and the exercising of judgment are appropriate relate to, valuation allowances for receivables and inventory, valuation of contingent consideration and warrant liabilities, realization of intangible and other long-lived assets, product sales allowances and reserves, share-based payments and income taxes including deferred tax assets and liabilities. Estimates are based on historical experience and other assumptions that are considered appropriate in the circumstances. They are continuously reviewed but may vary from the actual values.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q2	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	2300000	usd
CY2022Q4	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	2400000	usd
CY2023Q2	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	2300000	usd
CY2022Q4	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	2400000	usd
CY2023Q2	BFRI	Startup Cost Financing StartupCostFinancing	7300000	usd
CY2022Q4	BFRI	Startup Cost Financing StartupCostFinancing	7300000	usd
CY2023Q2	BFRI	Contract Asset ContractAsset	-179000	usd
CY2022Q4	BFRI	Contract Asset ContractAsset	-358000	usd
CY2023Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	9421000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	9342000	usd
CY2023Q2	BFRI	Stock Issued During Period Shares Investment In Equity Securities StockIssuedDuringPeriodSharesInvestmentInEquitySecurities	6280396	shares
CY2022Q4	BFRI	Stock Issued During Period Shares Investment In Equity Securities StockIssuedDuringPeriodSharesInvestmentInEquitySecurities	6446946	shares
CY2022Q4	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	2400000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-100000	usd
CY2023Q2	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	2300000	usd
CY2021Q4	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	6200000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-1900000	usd
CY2022Q2	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	4300000	usd
CY2022Q4	BFRI	Fair Value Warrant Liability Purchase Warrant FairValueWarrantLiabilityPurchaseWarrant	2843000	usd
CY2021Q4	BFRI	Fair Value Warrant Liability Purchase Warrant FairValueWarrantLiabilityPurchaseWarrant	12854000	usd
	BFRI	Fair Value Warrant Issuance Of New Derivative Liabilities FairValueWarrantIssuanceOfNewDerivativeLiabilities	9274000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1403000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-14082000	usd
CY2023Q2	BFRI	Fair Value Warrant Liability Purchase Warrant FairValueWarrantLiabilityPurchaseWarrant	1440000	usd
CY2022Q2	BFRI	Fair Value Warrant Liability Purchase Warrant FairValueWarrantLiabilityPurchaseWarrant	8046000	usd
CY2021Q4	BFRI	Revenue From Contract With Customer Allowances And Reserves RevenueFromContractWithCustomerAllowancesAndReserves	246000	usd
	BFRI	Revenue From Contract With Customer Allowances And Reserves Provision Related To Current Period RevenueFromContractWithCustomerAllowancesAndReservesProvisionRelatedToCurrentPeriod	525000	usd
	BFRI	Revenue From Contract With Customer Allowances And Reserves Credit Payments Made During Period RevenueFromContractWithCustomerAllowancesAndReservesCreditPaymentsMadeDuringPeriod	440000	usd
CY2022Q2	BFRI	Revenue From Contract With Customer Allowances And Reserves RevenueFromContractWithCustomerAllowancesAndReserves	331000	usd
CY2022Q4	BFRI	Revenue From Contract With Customer Allowances And Reserves RevenueFromContractWithCustomerAllowancesAndReserves	82000	usd
CY2022Q4	BFRI	Revenue From Contract With Customer Allowances And Reserves RevenueFromContractWithCustomerAllowancesAndReserves	82000	usd
	BFRI	Revenue From Contract With Customer Allowances And Reserves Provision Related To Current Period RevenueFromContractWithCustomerAllowancesAndReservesProvisionRelatedToCurrentPeriod	202000	usd
	BFRI	Revenue From Contract With Customer Allowances And Reserves Credit Payments Made During Period RevenueFromContractWithCustomerAllowancesAndReservesCreditPaymentsMadeDuringPeriod	132000	usd
CY2023Q2	BFRI	Revenue From Contract With Customer Allowances And Reserves RevenueFromContractWithCustomerAllowancesAndReserves	152000	usd
CY2023Q2	BFRI	Revenue From Contract With Customer Allowances And Reserves RevenueFromContractWithCustomerAllowancesAndReserves	152000	usd
CY2023Q2	BFRI	Stock Issued During Period Shares Investment In Equity Securities StockIssuedDuringPeriodSharesInvestmentInEquitySecurities	6280396	shares
CY2022Q4	BFRI	Stock Issued During Period Shares Investment In Equity Securities StockIssuedDuringPeriodSharesInvestmentInEquitySecurities	6446946	shares
	us-gaap	Equity Method Investment Additional Information EquityMethodInvestmentAdditionalInformation	3,377,346
	us-gaap	Proceeds From Sale Of Equity Securities Fv Ni ProceedsFromSaleOfEquitySecuritiesFvNi	200000	usd
CY2023Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1482000	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-4424000	usd
CY2023Q2	BFRI	Net Losses Recognized During Period On Equity Securities Sold NetLossesRecognizedDuringPeriodOnEquitySecuritiesSold	-75000	usd
	BFRI	Net Losses Recognized During Period On Equity Securities Sold NetLossesRecognizedDuringPeriodOnEquitySecuritiesSold	-75000	usd
CY2023Q2	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-1407000	usd
	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-4349000	usd
CY2023Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	200000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	100000	usd
CY2023Q2	us-gaap	Finite Lived License Agreements Gross FiniteLivedLicenseAgreementsGross	4600000	usd
CY2022Q4	us-gaap	Finite Lived License Agreements Gross FiniteLivedLicenseAgreementsGross	4600000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1777000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1568000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2823000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3032000	usd
CY2023Q2	us-gaap	Finite Lived License Agreements Gross FiniteLivedLicenseAgreementsGross	4600000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P11Y
CY2023Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	100000	usd
CY2022Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	100000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	200000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	200000	usd
CY2023Q2	us-gaap	Security Deposit SecurityDeposit	250000	usd
CY2023Q2	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	4200000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4453000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17208000	usd
CY2023Q2	us-gaap	Restricted Cash Equivalents Noncurrent RestrictedCashEquivalentsNoncurrent	200000	usd
CY2022Q4	us-gaap	Restricted Cash Equivalents Noncurrent RestrictedCashEquivalentsNoncurrent	200000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4653000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	17408000	usd
CY2023Q2	BFRI	Legal Settlement Expenses Current LegalSettlementExpensesCurrent	6094000	usd
CY2022Q4	BFRI	Legal Settlement Expenses Current LegalSettlementExpensesCurrent	6207000	usd
CY2023Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2816000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2850000	usd
CY2023Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1163000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1353000	usd
CY2023Q2	BFRI	Accrued Product Revenue Allowances And Reserves AccruedProductRevenueAllowancesAndReserves	152000	usd
CY2022Q4	BFRI	Accrued Product Revenue Allowances And Reserves AccruedProductRevenueAllowancesAndReserves	82000	usd
CY2023Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	511000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	372000	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10736000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10864000	usd
	us-gaap	Line Of Credit Facility Annual Principal Payment LineOfCreditFacilityAnnualPrincipalPayment	650000	usd
CY2023Q2	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.0531	pure
CY2023Q2	us-gaap	Line Of Credit LineOfCredit	200000	usd
CY2023Q2	BFRI	Legal Settlements Receivable Percentage LegalSettlementsReceivablePercentage	0.50	pure
	us-gaap	Equity Method Investment Additional Information EquityMethodInvestmentAdditionalInformation	3,377,346
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	15000000	shares
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	86951	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	62.16
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	22477	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	13.98
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	20419	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	54.14
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	89009	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	51.84
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y7M24D
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	13000	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	26042000	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	64.95
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y6M14D
CY2023Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	1400000	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y1M6D
CY2023Q2	BFRI	Interest Expenses InterestExpenses	32000	usd
CY2022Q2	BFRI	Interest Expenses InterestExpenses	3000	usd
	BFRI	Interest Expenses InterestExpenses	33000	usd
	BFRI	Interest Expenses InterestExpenses	7000	usd
CY2023Q2	BFRI	Contract Asset Interest Expense ContractAssetInterestExpense	89000	usd
CY2022Q2	BFRI	Contract Asset Interest Expense ContractAssetInterestExpense	89000	usd
	BFRI	Contract Asset Interest Expense ContractAssetInterestExpense	179000	usd
	BFRI	Contract Asset Interest Expense ContractAssetInterestExpense	179000	usd
CY2023Q2	us-gaap	Interest Income Operating InterestIncomeOperating	40000	usd
CY2022Q2	us-gaap	Interest Income Operating InterestIncomeOperating	53000	usd
	us-gaap	Interest Income Operating InterestIncomeOperating	94000	usd
	us-gaap	Interest Income Operating InterestIncomeOperating	110000	usd
CY2023Q2	us-gaap	Interest Income Other InterestIncomeOther	2000	usd
CY2022Q2	us-gaap	Interest Income Other InterestIncomeOther	1000	usd
	us-gaap	Interest Income Other InterestIncomeOther	4000	usd
	us-gaap	Interest Income Other InterestIncomeOther	5000	usd
CY2023Q2	us-gaap	Interest Expense InterestExpense	79000	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	38000	usd
	us-gaap	Interest Expense InterestExpense	114000	usd
	us-gaap	Interest Expense InterestExpense	71000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-9837000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-850000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-17315000	usd
	us-gaap	Net Income Loss NetIncomeLoss	4711000	usd
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1360739	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	941175	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1359894	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	898444	shares
	BFRI	Stock Options And Restricted Stock Units StockOptionsAndRestrictedStockUnits	3765	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1360739	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	941175	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1359894	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	902209	shares
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-7.23
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.90
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-12.73
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	5.24
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-7.23
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.90
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-12.73
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	5.22
	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	option to extend the term of the lease for one five (5) year period
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	265000	usd
	BFRI	Interest On Lease Liabilities InterestOnLeaseLiabilities	37000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	302000	usd
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	293000	usd
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y29D
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0631	pure
CY2023Q2	us-gaap	Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear	270000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	541000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	350000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1161000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	72000	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	1089000	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	489000	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	600000	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	1089000	usd
CY2021Q4	us-gaap	Payments For Legal Settlements PaymentsForLegalSettlements	22500000	usd
	us-gaap	Description Of Nature And Effect Of Significant Changes During Period Affecting Comparability DescriptionOfNatureAndEffectOfSignificantChangesDuringPeriodAffectingComparability	The Company matches 50% of employee contributions up to a maximum of 6% of employees’ salary.
CY2023Q2	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	100000	usd
CY2022Q2	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	100000	usd
	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	200000	usd
	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	100000	usd
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	15000000	shares
CY2023Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	100.00

Files In Submission

Name	View Source	Status
0001493152-23-027701-index-headers.html	Edgar Link	pending
0001493152-23-027701-index.html	Edgar Link	pending
0001493152-23-027701.txt	Edgar Link	pending
0001493152-23-027701-xbrl.zip	Edgar Link	pending
bfri-20230630.xsd	Edgar Link	pending
ex10-1.htm	Edgar Link	pending
ex10-1_001.jpg	Edgar Link	pending
ex10-1_002.jpg	Edgar Link	pending
ex10-1_003.jpg	Edgar Link	pending
ex10-1_004.jpg	Edgar Link	pending
ex10-1_005.jpg	Edgar Link	pending
ex10-1_006.jpg	Edgar Link	pending
ex10-1_007.jpg	Edgar Link	pending
ex10-1_008.jpg	Edgar Link	pending
ex10-1_009.jpg	Edgar Link	pending
ex10-1_010.jpg	Edgar Link	pending
ex10-1_011.jpg	Edgar Link	pending
ex10-1_012.jpg	Edgar Link	pending
ex10-1_013.jpg	Edgar Link	pending
ex10-1_014.jpg	Edgar Link	pending
ex10-1_015.jpg	Edgar Link	pending
ex10-1_016.jpg	Edgar Link	pending
ex10-1_017.jpg	Edgar Link	pending
ex10-1_018.jpg	Edgar Link	pending
ex10-1_019.jpg	Edgar Link	pending
ex10-1_020.jpg	Edgar Link	pending
ex10-1_021.jpg	Edgar Link	pending
ex10-1_022.jpg	Edgar Link	pending
ex10-1_023.jpg	Edgar Link	pending
ex10-1_024.jpg	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
bfri-20230630_def.xml	Edgar Link	unprocessable
bfri-20230630_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
bfri-20230630_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
bfri-20230630_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BFRI
Biofrontera Inc. Stock $bfri

2023 Q3 Form 10-Q Financial Statement

#000149315223027701 Filed on August 11, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BFRI Biofrontera Inc. Stock $bfri

2023 Q3 Form 10-Q Financial Statement

#000149315223027701 Filed on August 11, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BFRI
Biofrontera Inc. Stock $bfri